The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company’s key technology platform, its method for 3-dimensional expansion of placental and adipose (fat) derived cells. It also covers the composition of cells derived using this method.
"We believe Pluristem is the global leader in the commercial-scale production of placenta-derived cells. In our manufacturing facility, we use proprietary 3-dimensional cell expansion technology that gives us the ability to precisely control cell growth based on the intended indication to be treated. Our ability to do this on a large scale is one of our key assets," stated Pluristem CEO Zami Aberman.
"This patent issued by India is an important part of our global IP strategy to protect our breakthrough cell production methods in high-value and emerging healthcare markets where we see future potential for growth," Aberman added.
Pluristem Therapeutics is a developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases.
PLX cells are grown using the Company’s proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.